The UK Vaping Industry Association (UKVIA) has welcomed the first evidence review of e-cigarettes released by the Office of Health Improvement and Disparities (OHID) with regards to health benefits and differences.
John Dunn (pictured: UKVIA)
The latest review on e-cigarettes builds upon evidence collected by its predecessor, the Public Health England (PHE), and further emphasizes the role that e-cigarettes can play in improving public health.
We are pleased to see that the experts participating in this latest review continue to estimate that the harm from e-cigarettes is at least 95% lower than combustible tobacco and that it 'only represents a small fraction of smoking risk,' " said John Dunne, CEO of UKVIA in a statement. "This figure was first disclosed in 2015 by the then PHE in what was described as a milestone review, and behind this statistical data, statements regarding the significantly lower harm of vaping compared to smoking continue to be cited by health organizations in the UK today.
Duncan Selbie stated, "evidence shows that the relative exposure to electronic cigarettes is significantly lower compared to smoking, and these biomarkers are linked to risks of cancer, respiratory and cardiovascular diseases, and other health conditions that cause several thousands of deaths every year." "Our own youth prevention task force is working tirelessly with trade standards, retailers, and brand owners to prevent youth access to electronic cigarettes. We have recently presented recommendations to the Department of Health and Social Care aimed at reducing the sales of electronic cigarettes to minors from the source. These include introducing a retailer licensing or approved retailer and distributor scheme; imposing fines of at least £10,000 per transaction for traders who disregard UK law; and introducing a national testing and procurement program to ensure all retail businesses meet high standards in preventing youth access to electronic cigarettes.
Statement:
This article is compiled from third-party information and is intended for industry communication and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its contents. The translation of this article is solely for the purpose of industry exchange and research.
Due to limitations in the level of translation expertise, the translated article may not fully convey the original meaning. Therefore, please refer to the original article for accuracy.
2FIRSTS maintains full alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to remove it.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
